Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Huppert

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
The American Journal of Psychiatry|December 31, 2004
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorderEdna B Foa, Michael R Liebowitz, Michael J Kozak, et al.
Depression and Anxiety|July 27, 2004
Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorderH Blair Simpson, Michael R Liebowitz, Edna B Foa, et al.
The American Journal of Psychiatry|March 5, 2008
A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorderHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
The Journal of Clinical Psychiatry|June 14, 2013
Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, Michael R Liebowitz, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, David Rosenfield, et al.
JAMA Psychiatry|September 13, 2013
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trialHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
The Psychiatric Clinics of North America|May 9, 2024
Improving Exposure Therapy: Rationale and Design of an International ConsortiumJasper A J Smits, Jonathan S Abramowitz, Joanna J Arch, et al.
Clinical Psychological Science : a Journal of the Association for Psychological Science|August 26, 2025
Mechanisms of Change in Exposure Therapy for Anxiety and Related Disorders: A Research AgendaKristen Benito, Andre Pittig, Jonathan Abramowitz, et al.
Journal of Consulting and Clinical Psychology|August 8, 2020
The reciprocal relationship between alliance and early treatment symptoms: A two-stage individual participant data meta-analysisChristoph Flückiger, Julian Rubel, A C Del Re, et al.
JAMA Psychiatry|January 26, 2022
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical TrialEdna B Foa, Helen Blair Simpson, Thea Gallagher, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
The American Journal of Psychiatry|December 31, 2004
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorderEdna B Foa, Michael R Liebowitz, Michael J Kozak, et al.
Depression and Anxiety|July 27, 2004
Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorderH Blair Simpson, Michael R Liebowitz, Edna B Foa, et al.
The American Journal of Psychiatry|March 5, 2008
A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorderHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
The Journal of Clinical Psychiatry|June 14, 2013
Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, Michael R Liebowitz, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, David Rosenfield, et al.
JAMA Psychiatry|September 13, 2013
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trialHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
The Psychiatric Clinics of North America|May 9, 2024
Improving Exposure Therapy: Rationale and Design of an International ConsortiumJasper A J Smits, Jonathan S Abramowitz, Joanna J Arch, et al.
Clinical Psychological Science : a Journal of the Association for Psychological Science|August 26, 2025
Mechanisms of Change in Exposure Therapy for Anxiety and Related Disorders: A Research AgendaKristen Benito, Andre Pittig, Jonathan Abramowitz, et al.
Journal of Consulting and Clinical Psychology|August 8, 2020
The reciprocal relationship between alliance and early treatment symptoms: A two-stage individual participant data meta-analysisChristoph Flückiger, Julian Rubel, A C Del Re, et al.
JAMA Psychiatry|January 26, 2022
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical TrialEdna B Foa, Helen Blair Simpson, Thea Gallagher, et al.
Pageof 14